WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H527680
CAS#: 1811510-56-1 (free base)
Description: PF-06260933 is a potent and highly selective inhibitor of MAP4K4.
Hodoodo Cat#: H527680
Name: PF-06260933
CAS#: 1811510-56-1 (free base)
Chemical Formula: C16H13ClN4
Exact Mass: 296.08
Molecular Weight: 296.758
Elemental Analysis: C, 64.76; H, 4.42; Cl, 11.95; N, 18.88
Related CAS #: 1883548-86-4 (2HCl) 1811510-56-1 (free base) 2118243-34-6 (HCl),
Synonym: PF06260933; PF 06260933; PF-06260933; PF6260933; PF 6260933; PF-6260933;
IUPAC/Chemical Name: 5-(4-Chlorophenyl)-[3,3']bipyridinyl-6,6'-diamine
InChi Key: KHPCIHZXOGHCLY-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H13ClN4/c17-13-4-1-10(2-5-13)14-7-12(9-21-16(14)19)11-3-6-15(18)20-8-11/h1-9H,(H2,18,20)(H2,19,21)
SMILES Code: NC1=C(C2=CC=C(Cl)C=C2)C=C(C3=CC=C(N)N=C3)C=N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 296.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Roth Flach RJ, Skoura A, Matevossian A, Danai LV, Zheng W, Cortes C, Bhattacharya SK, Aouadi M, Hagan N, Yawe JC, Vangala P, Menendez LG, Cooper MP, Fitzgibbons TP, Buckbinder L, Czech MP. Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun. 2015 Dec 21;6:8995. doi: 10.1038/ncomms9995. PubMed PMID: 26688060; PubMed Central PMCID: PMC4703891.
2: Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, Ford K, Guimarães CR, Hepworth D, Jiao W, LaPerle J, Liu S, Londregan A, Loria PM, Mathiowetz AM, Munchhof M, Orr ST, Petersen DN, Price DA, Skoura A, Smith AC, Wang J. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33. doi: 10.1021/acsmedchemlett.5b00215. eCollection 2015 Nov 12. PubMed PMID: 26617966; PubMed Central PMCID: PMC4645242.